CN113549669A - 一种鸡ezh2基因对肿瘤性疾病影响的研究方法 - Google Patents
一种鸡ezh2基因对肿瘤性疾病影响的研究方法 Download PDFInfo
- Publication number
- CN113549669A CN113549669A CN202110728594.8A CN202110728594A CN113549669A CN 113549669 A CN113549669 A CN 113549669A CN 202110728594 A CN202110728594 A CN 202110728594A CN 113549669 A CN113549669 A CN 113549669A
- Authority
- CN
- China
- Prior art keywords
- ezh2
- chicken
- protein
- gene
- mdv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 59
- 101150090105 Ezh2 gene Proteins 0.000 title claims abstract description 21
- 201000010099 disease Diseases 0.000 title claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 21
- 230000001613 neoplastic effect Effects 0.000 title claims abstract description 19
- 238000011160 research Methods 0.000 title claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 94
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims abstract description 91
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims abstract description 91
- 101100024330 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MSB1 gene Proteins 0.000 claims abstract description 58
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 53
- 230000014509 gene expression Effects 0.000 claims abstract description 44
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 38
- 238000012258 culturing Methods 0.000 claims abstract description 14
- 230000035755 proliferation Effects 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 10
- 230000004663 cell proliferation Effects 0.000 claims abstract description 7
- 230000009471 action Effects 0.000 claims abstract description 6
- 230000007246 mechanism Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 76
- 239000000243 solution Substances 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 238000003753 real-time PCR Methods 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 17
- 230000008569 process Effects 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 14
- 108010078791 Carrier Proteins Proteins 0.000 claims description 13
- 102000014914 Carrier Proteins Human genes 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 239000006166 lysate Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000005457 ice water Substances 0.000 claims description 8
- 108010087230 Sincalide Proteins 0.000 claims description 7
- 238000010609 cell counting kit-8 assay Methods 0.000 claims description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 102000016943 Muramidase Human genes 0.000 claims description 4
- 108010014251 Muramidase Proteins 0.000 claims description 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 229960000274 lysozyme Drugs 0.000 claims description 4
- 235000010335 lysozyme Nutrition 0.000 claims description 4
- 239000004325 lysozyme Substances 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 210000003771 C cell Anatomy 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 3
- 239000012295 chemical reaction liquid Substances 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims description 3
- 238000007405 data analysis Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 238000002123 RNA extraction Methods 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 35
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108010026552 Proteome Proteins 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 101150029683 gB gene Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 102000058017 Enhancer of Zeste Homolog 2 Human genes 0.000 description 2
- 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 2
- 208000006758 Marek Disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OSXFATOLZGZLSK-UHFFFAOYSA-N 6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)-N-[1-(phenylmethyl)-4-piperidinyl]-4-quinazolinamine Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 OSXFATOLZGZLSK-UHFFFAOYSA-N 0.000 description 1
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 description 1
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 description 1
- 108010016918 Histone-Lysine N-Methyltransferase Proteins 0.000 description 1
- 102000000581 Histone-lysine N-methyltransferase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010031571 Marek's disease virus glycoprotein B Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种鸡EZH2基因对肿瘤性疾病影响的研究方法,包括S1.纯化鸡EZH2原核蛋白,得到EZH2蛋白样品;S2.将纯化后的鸡EZH2原核表达蛋白与MSB1细胞共同培养,测定EZH2原核表达蛋白对MSB1细胞增殖的影响;S3.于不同时间提取细胞总RNA,检测MDV相关基因的表达水平并进行分析,测定EZH2原核表达蛋白对MDV相关基因的表达水平的影响;实验证明,鸡EZH2蛋白可影响MSB1细胞的增殖,且影响该细胞中MDV Meq和gB基因的表达,为进一步探究鸡EZH2在MDV感染致肿瘤中的作用机制研究奠定了基础。
Description
技术领域
本发明涉及基因治疗技术领域,具体涉及一种鸡EZH2基因对肿瘤性疾病影响的研究方法。
背景技术
EZH2(enhancer of zeste homolog 2)即Zeste增强子同源物2,是PRC2(多梳蛋白抑制复合体2)的主要组成部分,又可以称之为组蛋白赖氨酸甲基转移酶,表观遗传学领域的研究和实验已经证明靶向EZH2抑制剂可抑制PRC2的致癌活性,能够对癌细胞的发生、入侵与扩散形成一定的阻碍作用;由此可见EZH2在靶向治疗恶性疾病领域中的重要意义;
马立克氏病(MD)是由马立克氏病毒(Marek's disease virus,MDV)引起的高度传染性肿瘤性疾病,以引起T细胞瘤为特点,Meq(MDV Eco Q片段编码蛋白)是MDV基因组中重要的致癌基因,在潜伏肿瘤细胞中始终表达。Meq编码bZIP蛋白,其在N末端具有亮氨酸拉链结构域,在C末端具有富含脯氨酸的反式激活结构域;
而对于鸡EZH2基因与MDV基因组之间的靶向性关系,在现有技术中并没有相关记载。
发明内容
针对上述存在的问题,本发明旨在提供一种鸡EZH2基因对肿瘤性疾病影响的研究方法,本方法通过对鸡EZH2基因对肿瘤性疾病影响的研究,证明鸡EZH2蛋白可抑制MSB1的增殖,且影响该细胞中MDV Meq和gB基因的表达,为进一步探究鸡EZH2在MDV感染致肿瘤中的作用机制研究奠定了基础。
为了实现上述目的,本发明所采用的技术方案如下:
一种鸡EZH2基因对肿瘤性疾病影响的研究方法,所述的研究方法包括步骤
S1.纯化鸡EZH2原核蛋白,得到含有纯化的His标签EZH2蛋白样品;
S2.将纯化后的鸡EZH2原核表达蛋白与MSB1细胞共同培养,测定EZH2原核表达蛋白对MSB1细胞增殖的影响;
S3.在步骤S2的基础上,于不同时间点提取细胞总RNA,检测MDV相关基因Meq、gB的表达水平并进行分析,测定EZH2原核表达蛋白对MDV相关基因Meq、gB的表达水平的影响。
优选的,步骤S1所述的鸡EZH2原核蛋白纯化的过程包括:
S101.将含有鸡EZH2原核表达载体的大肠杆菌Rosetta(PET-32a-EZH2)用1mmol诱导剂IPTG、29℃、诱导培养8h,收集细菌沉淀并称重,按每克细菌沉淀的湿重加入4ml非变性裂解液的比例加入非变性裂解液;
S102.加入溶菌酶至终浓度为1mg/ml,然后充分混匀,冰水浴30min;
S103.冰上超声裂解细菌,4℃、10000g下离心30min,将离心后的上清收于EP管中置于冰水浴或冰上;
S104.取1ml混合均匀的50%BeyoGoldTMHis-tag Purification Resin,4℃离心(1000g×10s)后弃去储存液,向纯化柱中的凝胶中加入0.5ml非变性裂解液,4℃离心弃平衡液,重复平衡2-3次之后加入细菌裂解液上清;
S105.将穿流液收集并重复上柱3-5次;
S106.然后取下纯化柱底部的盖子,使柱内液体由于重力的影响自然流出;
S107.每次加入非变性洗涤液0.5ml,之后连续洗柱5-6次,每次收集洗涤液20ul;
S108.最后把目的蛋白洗脱6-10次,每次都用非变性洗脱液0.5ml进行洗脱,得到含有纯化的His标签EZH2蛋白样品。
优选的,步骤S2所述的鸡EZH2原核表达蛋白与MSB1细胞共同培养的具体应用过程包括:
S201.用1640生长液将离心收集的细胞稀释至5.0×105个/mL,并取100μL/孔接种于96孔细胞培养板,处理组每孔加入不同浓度鸡EZH2原核蛋白,使终浓度分别为10、20、40、50μg/mL,对照组加入等体积相应浓度pet-32a空载体蛋白,各浓度设4个重复,并设不含抗体的正常细胞培养对照,轻轻摇晃混匀;
S202.在37℃细胞培养箱中培养24h、48h后每孔加入CCK-8试剂10μl,继续培养4h后,空白对照调零,酶标仪上测OD450。
优选的,步骤S3所述的鸡EZH2原核表达蛋白应用在MDV相关基因中的具体过程包括:
S301.用1640生长液将离心收集的细胞稀释至1.0×106个/mL,并取1mL/孔接种于96孔细胞培养板,处理组每孔加入不同浓度鸡EZH2原核蛋白,使终浓度为50μg/mL,对照组加入等体积相应浓度pet-32a空载体蛋白,各浓度设4个重复;
S302.继续培养24h和48h后,收集细胞,提取MSB1细胞总RNA;
S303.利用实时荧光定量PCR方法检测MDV相关基因表达。
优选的,步骤S303所述的MSB1细胞总RNA的提取过程包括
(1)收集2×106-1×107的MSB1细胞。2000×g离心5分钟,弃上清液;
(2)加入400μl缓冲液R-I,用装有21-25号针头的注射器反复抽吸8-10次,转入1.5ml离心管中;
(3)加入150μl缓冲液R-II并涡旋1分钟,在4℃下以12000×g离心5分钟;
(4)将上清液转移到1.5ml微量离心管中,加入250μl异丙醇并充分混合;
(5)将制备管柱置于2ml微量离心管中,将来自步骤(4)的结合混合物转移到制备管中,6000×g离心1分钟;
(6)弃滤液,将制备管放回2ml微量离心管中,并向制备管中加入700μlBufferW1A,12000×g离心1分钟;
(7)弃滤液,将制备管放回2ml微量离心管中,加入700μl Buffer W2,12000×g离心1分钟,以同样的方法再用700μl Buffer W2洗涤一次;
(8)弃滤液,将制备管置回2ml微量离心管中,12000×g离心1分钟;
(9)将制备管放入一干净的1.5ml离心管中,在制备管膜中央加70-100μl BufferTE或RNase-free水,室温静置1min,12000×g离心1min,洗脱得RNA。
优选的,步骤S304所述的实时荧光定量PCR方法检测MDV相关基因表达过程包括
(1)去除基因组DNA反应;
(2)进行MSB1细胞总RNA的反转录反应;
(3)利用TB Green Premix Ex Taq II方法进行Real Time PCR反应的操作方法配制Real Time反应反应液;
(4)进行Real Time PCR反应;
(5)计算MDV相关基因的表达量,进行数据分析。
优选的,步骤(3)所述的Real Time PCR反应过程中,Real Time反应反应液种需加入特异性引物和鸡内部参照基因,所述特异性引物和鸡内部参照基因包括
MDV Meq:F 5'-GTCCCCCCTCGATCTTTCTC-3′
R 5'-CGTCTGCTTCCTGCGTCTTC-3′;
gB:F 5'-ACCCCATTCGGTGGCTTTTC-3′
R 5'-GCGTCCAGTTGTCTGAGG-3′;
GAPDH:F 5'-TCTATCTCTTTGCTGGGACT-3′
R 5'-CTACAGCCAACTTTCATCAG-3′。
优选的,所述的鸡EZH2蛋白可抑制MSB1细胞的增殖,且影响该MSB1细胞中MDV Meq和gB基因的表达。
优选的,所述鸡EZH2蛋白具有活性,能够应用于其在鸡肿瘤性疾病中的作用机制研究。
本发明的有益效果是:本发明公开了一种鸡EZH2基因对肿瘤性疾病影响的研究方法,与现有技术相比,本发明的改进之处在于:
本发明通过以MDV感染的MSB1细胞为模型,纯化鸡EZH2蛋白并以不同浓度与MSB1共培养,于培养后24h和48h,采用CCK-8法测定鸡EZH2对MSB1细胞增殖的影响;同时以50ug/mL鸡EZH2蛋白作用MSB1细胞后,于不同时间点提取细胞总RNA,利用Real-time PCR检测MDV相关基因Meq、gB的表达水平并进行分析;
结果显示:以10ug/mL、20ug/mL、40ug/mL、50ug/mL不同浓度鸡EZH2作用于MSB1,CCK-8法检测MSB1细胞增殖,结果显示,低浓度(10ug/mL和20ug/mL)时,EZH2蛋白组抑制率与空载体蛋白对照组无明显差异(P>0.05),而高浓度(40ug/mL和50ug/mL)时EZH2蛋白组的抑制率显著高于空载体蛋白对照组(P<0.05);以50ug/mLEZH2蛋白与MSB1细胞共培养后24h,MSB1细胞抑制率与对照组无明显差异,而48h后显著高于对照组(P<0.05);在研究鸡EZH2对MDV相关基因的影响时发现,Meq和gB基因的相对表达量在24h和48h较对照组显著上调(P<0.05),这说明鸡EZH2原核表达蛋白对Meq和gB基因表达起到了促进作用;以上结果证实,鸡EZH2蛋白可抑制MSB1的增殖,且上调该细胞中MDV Meq和gB基因的表达,为进一步探究鸡EZH2在MDV感染致肿瘤中的作用机制研究奠定了基础,也为将EZH2基因能够应用于制备抑制肿瘤性疾病治疗的药物提供了理论依据。
附图说明
图1为本发明鸡EZH2基因对肿瘤性疾病影响的研究方法的流程图。
图2为本发明实施例1培养48h加入不同浓度EZH2蛋白MSB1细胞增殖能力检测柱状图。
图3为本发明实施例124h,48h后MSB1细胞的OD450比较图。
图4为本发明实施例1gB基因特异性检测曲线图。
图5为本发明实施例1Meq基因特异性检测曲线图。
图6为本发明实施例1gB基因的表达水平检测柱状图。
图7为本发明实施例1Meq基因的表达水平检测柱状图。
具体实施方式
为了使本领域的普通技术人员能更好的理解本发明的技术方案,下面结合附图和实施例对本发明的技术方案做进一步的描述。
实施例1:
参照附图1-7所示的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,具体包括材料准备过程、具体操作过程和实验结果分析过程,其中:
(一)材料准备过程过程包括:
1.载体与蛋白纯化
原核表达载体PET-32a原核表达载体及其宿主表达菌菌株Rosetta,含有EZH2目标基因重组的原核表达载体PET-32a-EZH2已构建得到,在河南科技大学动物疫病与公共安全实验室(动科楼404)保存,鸡EZH2原核表达蛋白纯化已完成;
2.本实验所用培养基
研究所用主要试剂及培养基如下表1:
表1:实验用培养基
3.主要仪器
本实验主要仪器如下表2:
表2:主要仪器
4.引物设计与合成
根据GenBank上已登录的EZH2(GenBank:Z48921.1)、gB(GenBank:NC_002229.3)、MDV Meq(GenBank:AB638843.1)以及鸡内部参照基因(GAPDH)(GenBank登录号:NM_204305.1)的mRNA序列;依照引物5.0来设计特异性引物,以避免形成稳定二聚体或引物和引物之间的发夹结构最终造成失配,Service bio有限公司合成用于扩增的引物序列示于表3所示:
表3:扩增引物
(二)具体研究过程,包括步骤
S1.纯化鸡EZH2原核蛋白
本实验采用BeyoGoldTMHis-tag Purification Resin进行蛋白纯化:
S101.为了达到充分重悬菌体这一操作目的,针对于EZH2蛋白这一目标蛋白,将含有鸡EZH2原核表达载体的大肠杆菌Rosetta(PET-32a-EZH2)用1mmol诱导剂IPTG、29℃、诱导培养8h,按每克细菌沉淀的湿重和加入4ml(2-5ml均可)非变性裂解液的比例,以此为根据加入非变裂解液;
S102.加入溶菌酶至终浓度为1mg/ml,然后充分混匀,准备一个烧杯,放入冰水混合物,将样品放置其中水浴30min;
其中:加入的溶菌酶:非变性裂解液=1:10的体积比;
S103.将上述水浴后的鸡EZH2未纯化蛋白在进行冰上超声裂解细菌,具体为:4℃离心机10000×g/min离心30min,将离心后的上清收于EP管中置于冰水浴或冰上;
S104.用移液枪来吸取混合均匀的50%BeyoGoldTMHis-tag Purification Resin(1ml)溶液,将溶液放于4℃离心机1000×g/min离心10s后弃去储存液,之后向纯化柱中的凝胶中加入0.5ml非变性裂解液,在4℃离心机1000×g/min离心10s后弃去储存液,然后缓慢重复平衡2-3次后,弃去上清,加入4ml细菌裂解液上清;
S105.将穿流液收集并重复上柱3-5次;
S106.然后取下纯化柱底部的盖子,使柱内液体由于重力的影响自然流出;可预留下穿流液20ul以作备用;
S107.每次加入非变性洗涤液0.5ml,之后连续洗柱5-6次,每次收集洗涤液20ul,以便用于接下来的分析检测用;
S108.最后把目的蛋白洗脱6-10次,每次都用非变性洗脱液0.5ml进行洗脱,将每次的洗脱液分别收集到10个标记好的EP管中,收集得到的洗脱液中含有纯化的His标签EZH2蛋白样品,即得到含有纯化的His标签EZH2蛋白样品;
注意:上述鸡EZH2原核蛋白的纯化过程是在EZH2原核蛋白最优表达条件下进行的纯化,所述最优表达条件为:
(1)温度为29°;
(2)诱导剂浓度为1.0mM IPTG;
(3)诱导时间为8h。
S2.将纯化后的鸡EZH2原核表达蛋白与MSB1细胞共同培养,观察EZH2原核表达蛋白对MSB1细胞增殖的影响:
S201.用1640生长液将离心收集的细胞稀释至5.0×105个/mL,并取100μL/孔接种于96孔细胞培养板,处理组每孔加入不同浓度鸡EZH2原核蛋白,使终浓度分别为10、20、40、50μg/mL,对照组加入等体积相应浓度pet-32a空载体蛋白,各浓度设4个重复,并设不含抗体的正常细胞培养对照,轻轻摇晃混匀;
S202.在37℃细胞培养箱中培养24h、48h后每孔加入CCK-8试剂10μl,继续培养4h后,空白对照调零,酶标仪上测OD450。
S3.在步骤S2的基础上,于不同时间点提取细胞总RNA,检测MDV相关基因Meq、gB的表达水平并进行分析,测定EZH2原核表达蛋白对MDV相关基因Meq、gB的表达水平的影响,具体包括步骤:
S301.用1640生长液将离心收集的细胞稀释至1.0×106个/mL,并取1mL/孔接种于96孔细胞培养板,处理组每孔加入不同浓度鸡EZH2原核蛋白,使终浓度为50μg/mL,对照组加入等体积相应浓度pet-32a空载体蛋白,各浓度设4个重复;
S302.然后将其接种至6孔内,每孔2mL,大约含有106个细胞,分别加入EZH2和空载体蛋白,使其总浓度均为50ug/mL,37℃孵育细胞48h;
S303.分别于6孔板中收集培养24h和48h的细胞,最后提取MSB1细胞总RNA,提取不同培养条件下的MSB1细胞总RNA的详细步骤如下:
(1)收集2×106-1×107的MSB1细胞,2000×g离心5分钟,弃上清液;
(2)加入400μl缓冲液R-I,用装有21-25号针头的注射器反复抽吸8-10次,转入1.5ml离心管(试剂盒内提供)中。
(3)加入150μl缓冲液R-II并涡旋1分钟,在4℃下以12000×g离心5分钟;
(4)将上清液转移到1.5ml微量离心管中,加入250μl异丙醇并充分混合;
(5)将制备管柱置于2ml微量离心管中,将来自步骤(4)的结合混合物转移到制备管中,6000×g离心1分钟;
(7)弃滤液,将制备管放回2ml微量离心管中,并向制备管中加入700μlBufferW1A,12000×g离心1分钟;
(8)弃滤液,将制备管放回2ml微量离心管中,加入700μl Buffer W2,12000×g离心1分钟,以同样的方法再用700μl Buffer W2洗涤一次。
(9)弃滤液,将制备管置回2ml微量离心管中,12000×g离心1分钟;
(10)将制备管放入一干净的1.5ml离心管(试剂盒内提供)中,在制备管膜中央加70-100μl Buffer TE或RNase-free水。室温静置1min,12000×g离心1min,洗脱得RNA;
S304.利用实时荧光定量PCR方法检测MDV相关基因表达,其具体包括:
(1)去除基因组DNA反应
分别提取不同蛋白共培养MSB1细胞总RNA后,去除提取总RNA中的基因组;按如下表4成分于冰上配制反应混合液,在此过程中为了保证反应液配制的准确性,进行各项反应时,可先按多于2个反应数量配制Master Mix,然后再分装到每个反应管中,最后加入RNA样品,反应液如表4:
表4:去除基因组DNA反应液
反应条件:42℃2min,4℃保存;
(2)进行MSB1细胞总RNA的反转录反应;
为了保证反应液配制的准确性,进行各项反应时,可先按多于2个反应数量配制Master Mix,然后再分装10μl到每个反应管中,轻柔混匀后立即进行反转录反应,反应液配置在冰水混合物上进行,反应液如下表5所示:
表5:反转录反应反应液
反应条件:37℃15min,85℃5sec,4℃保存;
(3)Real time PCR
按照TB Green Premix Ex Taq II(Tli RNaseH Plus)(Code No。RR820A/B)进行Real Time PCR反应的操作方法;按下列组份配制PCR反应液(反应液配制在冰水混合物进行),如表6所示:
表6:Real Time反应反应液
(4)进行Real Time PCR反应;
两步法PCR扩增标准程序:
Stage 1:预变性:95℃,30秒,一个循环
Stage 2:PCR反应:95℃,5秒;60℃,60秒;40个循环
(5)计算MDV相关基因的表达量,进行数据分析
采用2-△△Ct法计算各组MSB1细胞中MDV Meq和gB基因的相对表达量。
(三)实验结果分析过程
1.鸡EZH2原核表达蛋白对MSB1细胞增殖的影响
1.1不同浓度鸡EZH2原核表达蛋白进入MSB1细胞48h后用CCK-8法检测MSB1细胞的增殖率,如图2所示;
从图2可以观察到不同浓度的EZH2原核表达蛋白加入MSB1细胞后,低浓度(10ug/mL和20ug/mL)时,EZH2蛋白组抑制率与空载体蛋白对照组无明显差异(P>0.05),而高浓度(40ug/mL和50ug/mL)时EZH2蛋白组的抑制率显著高于空载体蛋白对照组(P<0.05),由此证明EZH2原核表达蛋白可抑制MSB1细胞的增殖,且其具有浓度依赖性;
1.2不同时间鸡EZH2原核表达蛋白对MSB1细胞增值的影响
不同时间鸡EZH2原核表达蛋白进入MSB1细胞24h,48h后用CCK-8法检测MSB1细胞的增殖,如图3所示;
通过图3可以看出,不同浓度鸡EZH2原核表达蛋白加入MSB1细胞后,24h时(P>0.05)EZH2蛋白组抑制率与空载体蛋白对照组差异不显著,而在48h时,与空载体蛋白相比,EZH2蛋白组显著抑制MSB1细胞增殖(P<0.01);
2.利用Real-time PCR检测MDV Meq、gB的表达水平
2.1溶解曲线的鉴定
(1)鸡EZH2原核表达蛋白加入MSB1细胞24h后,利用Real-timePCR检测MDV相关基因gB的基因表达水平,并做溶解曲线鉴定,如图4所示;
(2)鸡EZH2原核表达蛋白加入MSB1细胞24h后,利用Real-timePCR检测MDV相关基因Meq的基因表达水平,并做溶解曲线鉴定,并做图5表示;
通过对gB,Meq扩增产物的溶解曲线(见图4,图5)分析表明,各目标基因溶解曲线仅为单峰,无杂峰,表明Real-time PCR过程中只有一个扩增,说明建立的Real-time PCR方法特异性良好。
2.2 MDV gB基因相对表达水平变化
(1)鸡EZH2原核表达蛋白加入MSB1细胞24h,48h后,利用Real-timePCR检测MDV相关基因gB基因表达量,并做图6表示;结果显示,加入EZH2重组蛋白的MSB1细胞的MDV相关基因gB的相对表达量在24h和48h较对照组显著上调(P<0.01),表明与对照组相比较,gB的基因在鸡EZH2共培养的MSB1细胞中表达受到促进;
2.3MDV Meq基因相对表达水平变化
鸡EZH2原核表达蛋白加入MSB1细胞24h,48h后,利用Real-timePCR检测MDV相关基因Meq基因表达量,并图7表示;结果显示,加入EZH2蛋白的MSB1细胞的MDV相关基因Meq相对表达量在24h和48h较对照组显著上调(P<0.01),表明与对照组相比较,Meq的基因在鸡EZH2共培养的MSB1细胞中表达受到促进。
通过本研究中我们发现:
(1)鸡EZH2原核表达蛋白影响了MSB1细胞的增殖能力,该蛋白可抑制MSB1细胞的增殖,且这种抑制具有一定的浓度依赖性;
(2)利用荧光定量PCR技术检测鸡EZH2蛋白对MSB1细胞中MDV相关基因表达影响证实,相对空载体蛋白组,鸡EZH2蛋白对MDV相关gB基因和Meq基因表达水平表现为上调。
(3)鸡EZH2原核表达蛋白能够应用于其在鸡肿瘤性疾病的作用机制研究。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (9)
1.一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:包括步骤
S1.纯化鸡EZH2原核蛋白,得到含有纯化的His标签EZH2蛋白样品;
S2.将纯化后的鸡EZH2原核表达蛋白与MSB1细胞共同培养,测定EZH2原核表达蛋白对MSB1细胞增殖的影响;
S3.在步骤S2的基础上,于不同时间点提取细胞总RNA,检测MDV相关基因Meq、gB的表达水平并进行分析,测定EZH2原核表达蛋白对MDV相关基因Meq、gB的表达水平的影响。
2.根据权利要求1所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:步骤S1所述的鸡EZH2原核蛋白纯化的过程包括:
S101.将含有鸡EZH2原核表达载体的大肠杆菌Rosetta用1mmol诱导剂IPTG、29℃、诱导培养8h,收集细菌沉淀并称重,按每克细菌沉淀的湿重加入4ml非变性裂解液的比例加入非变性裂解液;
S102.加入溶菌酶至终浓度为1mg/ml,然后充分混匀,冰水浴30min;
S103.冰上超声裂解细菌,4℃、10000g下离心30min,将离心后的上清收于EP管中置于冰水浴或冰上;
S104.取1ml混合均匀的50%BeyoGoldTMHis-tag Purification Resin,4℃离心后弃去储存液,向纯化柱中的凝胶中加入0.5ml非变性裂解液,4℃离心弃平衡液,重复平衡2-3次之后加入细菌裂解液上清;
S105.将穿流液收集并重复上柱3-5次;
S106.然后取下纯化柱底部的盖子,使柱内液体由于重力的影响自然流出;
S107.每次加入非变性洗涤液0.5ml,之后连续洗柱5-6次,每次收集洗涤液20ul;
S108.最后把目的蛋白洗脱6-10次,每次都用非变性洗脱液0.5ml进行洗脱,得到含有纯化的His标签EZH2蛋白样品。
3.根据权利要求1所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:步骤S2所述的鸡EZH2原核表达蛋白与MSB1细胞共同培养的具体应用过程包括:
S201.用1640生长液将离心收集的细胞稀释至5.0×105个/mL,并取100μL/孔接种于96孔细胞培养板,处理组每孔加入不同浓度鸡EZH2原核蛋白,使终浓度分别为10、20、40、50μg/mL,对照组加入等体积相应浓度pet-32a空载体蛋白,各浓度设4个重复,并设不含抗体的正常细胞培养对照,轻轻摇晃混匀;
S202.在37℃细胞培养箱中培养24h、48h后每孔加入CCK-8试剂10μl,继续培养4h后,空白对照调零,酶标仪上测OD450。
4.根据权利要求1所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:步骤S3所述的鸡EZH2原核表达蛋白应用在MDV相关基因中的具体过程包括:
S301.用1640生长液将离心收集的细胞稀释至1.0×106个/mL,并取1mL/孔接种于96孔细胞培养板,处理组每孔加入不同浓度鸡EZH2原核蛋白,使终浓度为50μg/mL,对照组加入等体积相应浓度pet-32a空载体蛋白,各浓度设4个重复;
S302.继续培养24h和48h后,收集细胞,提取MSB1细胞总RNA;
S303.利用实时荧光定量PCR方法检测MDV相关基因表达。
5.根据权利要求3所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:步骤S303所述的MSB1细胞总RNA的提取过程包括
(1)收集2×106-1×107的MSB1细胞。2000×g离心5分钟,弃上清液;
(2)加入400μl缓冲液R-I,用装有21-25号针头的注射器反复抽吸8-10次,转入1.5ml离心管中;
(3)加入150μl缓冲液R-II并涡旋1分钟,在4℃下以12000×g离心5分钟;
(4)将上清液转移到1.5ml微量离心管中,加入250μl异丙醇并充分混合;
(5)将制备管柱置于2ml微量离心管中,将来自步骤(4)的结合混合物转移到制备管中,6000×g离心1分钟;
(6)弃滤液,将制备管放回2ml微量离心管中,并向制备管中加入700μl BufferW1A,12000×g离心1分钟;
(7)弃滤液,将制备管放回2ml微量离心管中,加入700μl Buffer W2,12000×g离心1分钟,以同样的方法再用700μl Buffer W2洗涤一次;
(8)弃滤液,将制备管置回2ml微量离心管中,12000×g离心1分钟;
(9)将制备管放入一干净的1.5ml离心管中,在制备管膜中央加70-100μl Buffer TE或RNase-free水,室温静置1min,12000×g离心1min,洗脱得RNA。
6.根据权利要求3所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:步骤S304所述的实时荧光定量PCR方法检测MDV相关基因表达过程包括
(1)去除基因组DNA反应;
(2)进行MSB1细胞总RNA的反转录反应;
(3)利用TB Green Premix Ex Taq II方法进行Real Time PCR反应的操作方法配制Real Time反应反应液;
(4)进行Real Time PCR反应;
(5)计算MDV相关基因的表达量,进行数据分析。
7.根据权利要求6所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:步骤(3)所述的Real Time PCR反应过程中,Real Time反应反应液种需加入特异性引物和鸡内部参照基因,所述特异性引物和鸡内部参照基因包括
MDV Meq:F 5'-GTCCCCCCTCGATCTTTCTC-3′
R 5'-CGTCTGCTTCCTGCGTCTTC-3′;
gB:F 5'-ACCCCATTCGGTGGCTTTTC-3′
R 5'-GCGTCCAGTTGTCTGAGG-3′;
GAPDH:F 5'-TCTATCTCTTTGCTGGGACT-3′
R 5'-CTACAGCCAACTTTCATCAG-3′。
8.根据权利要求1所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:所述的鸡EZH2蛋白可抑制MSB1细胞的增殖,且影响该MSB1细胞中MDV Meq和gB基因的表达。
9.根据权利要求8所述的一种鸡EZH2基因对肿瘤性疾病影响的研究方法,其特征在于:所述鸡EZH2蛋白具有活性,能够应用于其在鸡肿瘤性疾病中的作用机制研究。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110728594.8A CN113549669A (zh) | 2021-06-29 | 2021-06-29 | 一种鸡ezh2基因对肿瘤性疾病影响的研究方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110728594.8A CN113549669A (zh) | 2021-06-29 | 2021-06-29 | 一种鸡ezh2基因对肿瘤性疾病影响的研究方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113549669A true CN113549669A (zh) | 2021-10-26 |
Family
ID=78102542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110728594.8A Pending CN113549669A (zh) | 2021-06-29 | 2021-06-29 | 一种鸡ezh2基因对肿瘤性疾病影响的研究方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113549669A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105168199A (zh) * | 2015-07-30 | 2015-12-23 | 桂林医学院 | 莪术醇在制备靶向抑制肿瘤细胞ezh2蛋白的药物的应用 |
CN106074485A (zh) * | 2012-04-28 | 2016-11-09 | 张国营 | 茶氨酸在制备组蛋白转甲基酶ezh2抑制剂中的应用 |
CN111053784A (zh) * | 2019-12-11 | 2020-04-24 | 扬州大学 | 黄芩苷在制备用于鸡马立克氏病的药物中的应用 |
CN111394334A (zh) * | 2020-01-10 | 2020-07-10 | 中山大学 | 抑制ezh2活性的抗肿瘤多肽及其应用 |
-
2021
- 2021-06-29 CN CN202110728594.8A patent/CN113549669A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106074485A (zh) * | 2012-04-28 | 2016-11-09 | 张国营 | 茶氨酸在制备组蛋白转甲基酶ezh2抑制剂中的应用 |
CN105168199A (zh) * | 2015-07-30 | 2015-12-23 | 桂林医学院 | 莪术醇在制备靶向抑制肿瘤细胞ezh2蛋白的药物的应用 |
CN111053784A (zh) * | 2019-12-11 | 2020-04-24 | 扬州大学 | 黄芩苷在制备用于鸡马立克氏病的药物中的应用 |
CN111394334A (zh) * | 2020-01-10 | 2020-07-10 | 中山大学 | 抑制ezh2活性的抗肿瘤多肽及其应用 |
Non-Patent Citations (5)
Title |
---|
JIN WANG等: "Sodium tanshinone IIA sulfonate affects Marek’s disease virus replication by inhibiting gB", PHARM BIOL, vol. 54, no. 4, 1 October 2015 (2015-10-01), pages 701 - 704 * |
N AN等: "Growth inhibitive effect of betulinic acid combined with tripterine on MSB-1 cells and its mechanism", POULT SCI, vol. 94, no. 12, 31 December 2015 (2015-12-31), pages 2880 - 2886 * |
ZHAO CHUN-FANG等: "Knockdown of the Meq gene in Marek\'s disease tumor cell line MSB1 might induce cell apoptosis and inhibit cell proliferation and invasion", JOURNAL OF INTEGRATIVE AGRICULTURE, vol. 19, no. 11, 2 November 2020 (2020-11-02), pages 2767 - 2774, XP086295527, DOI: 10.1016/S2095-3119(20)63321-4 * |
冯春等: "姜黄素抑制马立克氏病病毒在CEF细胞中的复制", 中国动物传染病学报, vol. 28, no. 2, 17 September 2019 (2019-09-17), pages 72 - 79 * |
郁川: "鸡β2-微球蛋白在马立克氏病毒感染与致肿瘤中的作用研究", 中国博士学位论文全文数据库 农业科技辑, no. 1, 15 January 2015 (2015-01-15), pages 85 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9109259B2 (en) | Detection method for novel ROS1 fusions | |
CN1963511B (zh) | Dkk-1蛋白在癌症诊断中的应用 | |
CN107519193B (zh) | 食管鳞癌早期分子诊断标志物及其应用 | |
CN107164538B (zh) | 一种检测calr基因突变的内参扩增引物组合物及其扩增体系 | |
CN110066875B (zh) | 一种长链非编码RNA lncLCIR-1作为肺癌分子标志物的应用 | |
CN109913482B (zh) | Pik3ca-i874r突变基因及其在乳腺癌辅助诊断中的应用 | |
WO2011103770A1 (zh) | 用于定量检测braf突变的试剂盒 | |
WO2011079524A1 (zh) | 用于定量检测k-ras突变的试剂盒 | |
CN113549669A (zh) | 一种鸡ezh2基因对肿瘤性疾病影响的研究方法 | |
CN115287286B (zh) | 一种长链非编码RNA lnc1267在调节细胞增殖与存活中的应用 | |
CN110699487A (zh) | 用于诊断禽白血病病毒肿瘤发生的反义rna及制备方法、应用和构建过表达载体的引物 | |
CN111440868B (zh) | 喉鳞癌分子标记物hsa_circ_0018169及其检测方法和应用 | |
CN108949998B (zh) | 预测乳腺癌患者对抗her2治疗药物反应性的基因突变位点及其应用 | |
CN109913481B (zh) | PIK3CA基因g.179224821G>A突变及其在乳腺癌辅助诊断中的应用 | |
CN112094860A (zh) | 一种ctcf-eto2血液病的融合基因及其检测引物和应用 | |
WO2016179814A1 (zh) | 与乳头状甲状腺瘤相关的基因 | |
CN112501304A (zh) | miRNA-424作为脑垂体瘤诊断标志物的应用 | |
CN112538478A (zh) | 一种长链非编码RNA lncRNA070974及其应用 | |
CN111154883A (zh) | 一种乳腺癌相关基因PIK3CA位点g.179220986A>T突变体及其应用 | |
CN111172282A (zh) | 外泌体miRNA在制备肺癌早期诊断试剂盒中的应用及肺癌早期诊断检测试剂盒 | |
WO2014183301A1 (en) | Reagent and method for tumor detection and therapy | |
CN108866199B (zh) | 一种用于乳腺癌诊断mRNA标志物及其检测试剂盒与应用 | |
CN114438207B (zh) | 一种乳腺癌的环状rna生物标志物及其应用 | |
CN110684847B (zh) | 一种与乳腺癌发生发展相关的生物标志物的用途 | |
CN115323051B (zh) | 一种急性髓系白血病检测探针组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |